After several years of weak financial results, 2021 is the first year of positive operating results for NORCE and we are starting to see the intended synergies of standing together as a large institute.
Since its establishment, NORCE has sold several subsidiaries that have been started on the basis of results and innovations from our research. This has meant good liquidity for NORCE and we are well equipped for new research and innovative initiatives. Two of these companies, Gexcon and Prototech, were sold in 2021.
The research centre, the GenØk Centre for Biosafety in Tromsø became part of NORCE in December 2021. GenØk is a national centre for biosafety and conducts research on environmental, health and societal consequences of the use of genetic engineering and genetic modification. The centre focuses on the safe use of biotechnology.
Elisabeth Maråk Støle resigned from the position as CEO in January. Thor Arne Håverstad was appointed acting CEO until Kristin Wallevik took over as new CEO on 1 August. In 2021, we reorganised from six research departments into three divisions and three new executive vice presidents were recruited.
NORCE has identified four strategic priority areas for the period up to 2025, where we are gathering strength across the breadth of our research areas to enable good choices to be made for the future.